Research Papers:

EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression

Kaustubh Bhinge, Lin Yang, Simone Terra, Aqsa Nasir, Prasuna Muppa, Marie Christine Aubry, Joanne Yi, Nafiseh Janaki, Irina V. Kovtun, Stephen J. Murphy, Geoffrey Halling, Hamed Rahi, Aaron Mansfield, Mariza de Andrade, Ping Yang, George Vasmatzis, Tobias Peikert, Farhad Kosari _

Metrics: PDF 132 views  |   HTML 138 views  |   ?  


Kaustubh Bhinge1, Lin Yang2, Simone Terra6, Aqsa Nasir2, Prasuna Muppa6, Marie Christine Aubry6, Joanne Yi6, Nafiseh Janaki2, Irina V. Kovtun3, Stephen J. Murphy1, Geoffrey Halling1, Hamed Rahi1, Aaron Mansfield5, Mariza de Andrade4, Ping Yang4, George Vasmatzis1, Tobias Peikert7, Farhad Kosari1

1Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA

2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

3Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA

4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

5Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

6Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA

7Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA

Correspondence to:

Farhad Kosari, email: kosari.farhad@mayo.edu

Keywords: ASCL1, RET, EGFR, lung cancer, neuroendocrine

Received: April 10, 2016     Accepted: February 06, 2017     Published: February 24, 2017


Achaete-scute homolog 1 (ASCL1) is a neuroendocrine transcription factor specifically expressed in 10-20% of lung adenocarcinomas (AD) with neuroendocrine (NE) differentiation (NED). ASCL1 functions as an upstream regulator of the RET oncogene in AD with high ASCL1 expression (A+AD). RET is a receptor tyrosine kinase with two main human isoforms; RET9 (short) and RET51 (long). We found that elevated expression of RET51 associated mRNA was highly predictive of poor survival in stage-1 A+AD (p=0.0057). Functional studies highlighted the role of RET in promoting invasive properties of A+AD cells. Further, A+AD cells demonstrated close to 10 fold more sensitivity to epidermal growth factor receptor (EGFR) inhibitors, including gefitinib, than AD cells with low ASCL1 expression. Treatment with EGF robustly induced phosphorylation of RET at Tyr-905 in A+AD cells with wild type EGFR. This phosphorylation was blocked by gefitinib and by siRNA-EGFR. Immunoprecipitation experiments found EGFR in a complex with RET in the presence of EGF and suggested that RET51 was the predominant RET isoform in the complex. In the microarray datasets of stage-1 and all stages of A+AD, high levels of EGFR and RET RNA were significantly associated with poor overall survival (p < 0.01 in both analyses). These results implicate EGFR as a key regulator of RET activation in A+AD and suggest that EGFR inhibitors may be therapeutic in patients with A+AD tumors even in the absence of an EGFR or RET mutation.

Author Information

Kaustubh Bhinge

Lin Yang

Simone Terra

Aqsa Nasir

Prasuna Muppa

Marie Christine Aubry

Joanne Yi

Nafiseh Janaki

Irina V. Kovtun

Stephen J. Murphy

Geoffrey Halling

Hamed Rahi

Aaron Mansfield

Mariza de Andrade

Ping Yang

George Vasmatzis

Tobias Peikert

Farhad Kosari
Primary Contact  _

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15676